Opinion on Pharmaceuticals and Healthcare

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth: optimizing bazedoxifene's lifecycle strategy

Wyeth has received an approvable letter from the FDA which confirms that bazedoxifene, to be marketed as Viviant, is likely to be indicated for the prevention of postmenopausal osteoporosis. This is the first step in what Datamonitor expects to be a successful and maintained brand lifecycle management strategy.

Published By Datamonitor
25 Apr 2007
CommentWire
CommentWire

Wyeth: not SAD about Effexor approval

The expanding versatility of Wyeth's blockbuster Effexor is key to its continued success. Sales should top $2 billion in 2003. However, competition is strong with large players including Pfizer and GlaxoSmithKline battling for a share of the lucrative mood disorders market. Nevertheless, Effexor's advantageous mechanism of action and convenient once-daily dosage will provide the edge over rivals.

Published By Datamonitor
13 Feb 2003
CommentWire
CommentWire

Wyeth: job cuts for US sales force

About 1,200 US sales representatives at Wyeth have been notified this week that they are to lose their positions. The cuts come as part of a major company-wide restructuring program, announced nine weeks ago. Like many of its peers, Wyeth's US sales are struggling against increased competition from generic products: a trend which is forecast to intensify over the next five years.

Published By Datamonitor
28 Mar 2008
CommentWire
CommentWire

Wyeth: hanging onto the osteoporosis drug discovery bandwagon

Wyeth's [WYE] pipeline is looking bare, particularly in women's health, with only two linked candidates in trials for osteoporosis/menopause. Recent agreements with biotech firms Tanox [TNOX] and Galapagos Genomics show the company is finally following other osteoporosis players' examples in a bid to remain in this lucrative market.

Published By Datamonitor
21 Nov 2003
CommentWire
CommentWire

Wyeth: further evidence of HRT cancer link raises Aprela expectation

A new study supports the possible link between breast cancer and hormone replacement therapy in post-menopausal women, fuelling safety concerns which have threatened the market since 2002. Datamonitor believes that with such a strong need for safer treatments in this indication, Wyeth's pipeline drug Aprela is well positioned to capture a significant share of the market.

Published By Datamonitor
10 Feb 2009
CommentWire
CommentWire

Wyeth: Enbrel inflames profits

Wyeth has reported positive second quarter earnings, thanks in part to strong demand for the arthritis treatment Enbrel. With its launch in Japan already boosting sales, even with a drop in the drug's hard-sell marketing post-Vioxx, it is expected to remain well-positioned to carry the fight to Centocor's competing Remicade.

Published By Datamonitor
21 Jul 2005
CommentWire
CommentWire

Wyeth: Effexor XR is deemed effective

Wyeth has released the findings of the study, which pooled together results of eight double-blind studies and compared Effexor XR to a leading serotonin selective re-uptake inhibitor. Although the drug's sales should be high it could suffer at the hands of strong competition from Lilly's duloxetine.<BR />

Published By Datamonitor
13 Dec 2002
CommentWire
CommentWire

Wyeth: Effexor unsuitable for depressed children

Wyeth [WYE] has warned that its antidepressant Effexor (venlafaxine) is not effective for treating depression in children and teenagers, raising further concerns over the safety of prescribing antidepressants to children. However, due to the drug's ongoing success and growth it is unlikely this latest warning will have a significant effect on Effexor's sales.

Published By Datamonitor
08 Sep 2003
CommentWire
CommentWire

Wyeth: diversity key to growth

Wyeth's performance in 2002 was negatively affected by its heavy reliance on its Women's Health franchise. With the anticipated launch of Flumist, it is expected that 2003 will mark the beginning of Wyeth's transition from a reliance on HRT treatments to a more diversified portfolio.<BR />

Published By Datamonitor
05 Jun 2003
CommentWire
CommentWire

Wyeth: breast cancer prospects receive a blow

Wyeth has discontinued a phase III trial of temsirolimus plus letrozole in metastatic post-menopausal hormone-receptor positive breast cancer. This is a significant blow for the company due to the loss of earnings potential in the congested but lucrative breast cancer market. However, temsirolimus remains under development for a number of other tumors, and so hope for the drug candidate remains.

Published By Datamonitor
23 Mar 2006

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.